UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number: 001-40086
ALPHATON CAPITAL CORP
(Translation of registrant's name into English)
Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British
Virgin Islands, VG1110
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
INCORPORATION BY REFERENCE
This report on Form 6-K (including any exhibits attached hereto) shall
be deemed to be incorporated by reference into the registration statement on Forms S-8 (File Nos. 333-275842 and 333-289199) and Forms
F-3 (File Nos. 333-286961, 333-290827 and 333-291341) of the company (including any prospectuses forming a part of such registration statement)
and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently
filed or furnished.
ATM Agreement
On November 25, 2025, AlphaTON Capital Corp., (formerly
known as Portage Biotech, Inc.) (the “Company”) filed with the Securities and Exchange Commission (the “SEC”)
a prospectus supplement (the “ATM Prospectus”) for the offer and sale of up to $15,307,818 of our ordinary shares (the “Shares”)
pursuant an At-The Market-Offering Agreement (the “ATM Agreement”), with Chardan Capital Markets, LLC (“Chardan”),
dated July 31, 2025.
The offer and sale of the Shares, if any, will be made pursuant to a shelf
registration statement on Form F-3 and the related base prospectus (File No. 333-286961) initially filed by the Company with the SEC,
on May 5, 2025, as amended on May 12, 2025, and declared effective by the SEC on May 14, 2025, and the related ATM Prospectus.
The Shares may be offered and sold (A) in privately negotiated transactions
with the Company's consent, (B) as block transactions; or (C) by any other method permitted by law deemed to be an "at the market
offering" as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market, sales
made into any other existing trading market in the United States for the Ordinary Shares, and sales made to or through a market maker
other than on an exchange. The Agent is not required to sell any number or dollar amount of the Shares but will act as a sales agent
and use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations
to sell on the Company's behalf all of the Shares requested to be sold by the Company. The offering of the Shares pursuant to the ATM
Agreement and the ATM Prospectus will terminate upon the earlier of (a) the sale of the Shares pursuant to the ATM Prospectus having
an aggregate sales price of $15,307,818, or (b) termination of the ATM Agreement as permitted therein.
The Company will pay to the Agent a fixed cash commission rate equal to
3.0% of the gross sales price of any Shares sold under the ATM Agreement and has agreed to provide the Agent with customary indemnification
and contribution rights. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the
ATM Agreement.
The ATM Agreement also contains customary representations and warranties
and conditions to the sale of the Shares pursuant thereto.
The foregoing description of the ATM Agreement is not complete and is qualified
in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as an Exhibit 1.1 to this Report on
Form 6-K and is incorporated herein by reference. A copy of the opinion of Forbes Hare relating to the legality of the Shares is filed
as Exhibit 5.1 to this Report on Form 6-K and incorporated herein by reference.
This Report on Form 6-K shall not constitute an offer to sell or the solicitation
of an offer to buy the Ordinary Shares discussed herein, nor shall there be any offer, solicitation, or sale of securities in any state
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
state.
Exhibits
| 1.1 ** |
At The Market Offering Agreement, dated July 31, 2025, between Chardan Capital Markets, LLC and the Registrant. |
| |
|
| 5.1 * |
Opinion of Forbes Hare |
| |
|
| 23.1 * |
Consent of Forbes Hare (included in Exhibit 5.1) |
_______
* Filed herewith
** Previously filed
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
ALPHATON CAPITAL CORP |
| |
(Registrant) |
| |
|
| |
|
| Date: November 25, 2025 |
/s/ Wes Levitt |
| |
Wes Levitt |
| |
Chief Financial Officer |